TheraRadar
Data updated: May 26, 2026

TROSPIUM CHLORIDE

Urology Approved 2010-08-13

Trospium chloride helps patients with overactive bladder manage symptoms such as urinary frequency and a sudden, strong need to urinate. It is also used for individuals experiencing urge urinary incontinence. This medication is prescribed to improve bladder control by targeting the smooth muscle within the organ.

Source: FDA Label • HERITAGE PHARMS INC

How TROSPIUM CHLORIDE Works

This drug works by blocking the action of acetylcholine on muscarinic receptors in the bladder. This process reduces the tone of the bladder's smooth muscle, which helps alleviate overactive symptoms. It specifically targets these muscarinic receptors with minimal impact on nicotinic receptors at therapeutic levels.

Source: FDA Label
12
Indications
--
Phase 3 Trials
15
Years on Market

Details

Status
Prescription
First Approved
2010-08-13
Routes
ORAL
Dosage Forms
TABLET, CAPSULE, EXTENDED RELEASE

TROSPIUM CHLORIDE Approval History

2011
2012
2013
2014
2015
2016
2017
2018
2019
2020
2021
2022
2023
2024
2025
2026
Original
New Indication
New Form
Label Update
24 FDA actions from 2010 to 2025
Apr 2025 SUPPL
Label · Labeling
Jun 2024 ORIGINAL
Update
Oct 2022 SUPPL
Label · Labeling

What TROSPIUM CHLORIDE Treats

4 indications

TROSPIUM CHLORIDE is approved for 4 conditions since its original approval in 2010. These indications span multiple therapeutic areas including oncology, immunology, and more.

  • Overactive bladder
  • Urge urinary incontinence
  • Urinary urgency
  • Urinary frequency
Source: FDA Label

TROSPIUM CHLORIDE Competitive Set

Pro

Three rings of competition based on shared molecular targets and treated indications.

Unlock 7 more competitors across all three rings.
Upgrade to Pro

Filters applied: drops same-active-ingredient (505(b)(2) reformulations), route-mismatch (topical vs systemic), and cross-therapeutic-area matches in same-indication rings.

Drugs Similar to TROSPIUM CHLORIDE

3 of 12

FDA-approved drugs for similar conditions. Compare mechanisms and indications to understand treatment alternatives.

DARIFENACIN
DARIFENACIN HYDROBROMIDE
2 shared
MACLEODS PHARMS LTD
Shared indications:
Overactive BladderUrge Urinary Incontinence
DARIFENACIN HYDROBROMIDE
DARIFENACIN HYDROBROMIDE
2 shared
TORRENT
Shared indications:
Overactive BladderUrge Urinary Incontinence
DETROL LA
TOLTERODINE TARTRATE
2 shared
UPJOHN
Shared indications:
Overactive BladderUrge Urinary Incontinence
📋

Clinical Trial Registry

7 trials
Trial Sponsor ID Phase Status Title
NCT07063342 CN012-0043 U1111-1321-3511 Ph 1 recruiting A Study to Evaluate Novel KarX and KarT Prototypes Versus the KarXT and KarX-EC Reference Following Single Doses, and to Explore the Effect of Food After Multiple Doses of Selected Prototypes in Healthy Adult Participants
NCT01166438 ABC results posted PFDN 17 2U01HD041249, 2U10HD041250 Ph 3 completed Anticholinergic vs. Botox Comparison Study
NCT02831231 KAR-001 Ph 1 completed Pilot Study Comparing Effects of Xanomeline Alone to Xanomeline Plus Trospium
NCT01922115 ACE results posted 13-1352 Ph 4 completed The Effect of Anticholinergics on Cognitive Function in the Elderly
NCT01178827 results posted MA-SXR-09-005 Ph 4 completed Sanctura Muscarinic Receptor Antagonist Resists Transport (SMART-II) Trial
NCT00863551 results posted MA-SXR-09-001 SMART Trial Ph 4 completed Sanctura Muscarinic Receptor Antagonist Resists Transport (SMART) Trial
NCT01089751 results posted GMA-SXR-09-004 Ph 4 completed Efficacy of Sanctura XR (Trospium Chloride) for Reducing Overactive Bladder Symptoms in Female Subjects Refractory to Detrol LA (Tolterodine Tartrate Extended Release) Daily
🔬

Active Pipeline

Pro

Ongoing clinical trials by development phase

Loading...

Key Completed Trials

Pro

Completed studies with published results, ranked by significance

Loading...
📊

Trial Timeline

Full development history with FDA approval milestones

|
Loading...
Understanding FDA Approval Types
Count Type What it means
- ORIG Original approval - drug first enters market
- SUPPL - Efficacy New indication (new disease/condition approved)
- SUPPL - Labeling Label text changes (warnings, dosing updates)
- SUPPL - Manufacturing Production changes (new facility)
- SUPPL - Chemistry Formulation changes (new dosage strength)

Green lines in the timeline show ORIG and Efficacy approvals - the clinically meaningful milestones.

TROSPIUM CHLORIDE FDA Label Details

Indications & Usage

TROSPIUM CHLORIDE is indicated for the treatment of Overactive bladder; Urge urinary incontinence; Urinary urgency; Urinary frequency.

Looking for the branded version?

COBENFY

Full clinical data, patents, trials, and competitive landscape for trospium chloride.

See COBENFY

Data Sources

Data sourced from official FDA and NIH databases. Click links to verify on original sources.